Mucous membrane pemphigoid (MMP) is a heterogeneous group of chronic, autoimmune
subepithelial blistering diseases that predominantly involves the mucous membranes and …

Oral mucosal diseases represent several common conditions that affect all segments of the
general population. Some of these disorders present with signs and symptoms that are …

This guideline on mucous membrane pemphigoid (MMP) has been elaborated by the Task
Force for Autoimmune Blistering Diseases of the European Academy of Dermatology and …

Introduction Rituximab (RTX) is a monoclonal antibody targeting CD20, a transmembrane
protein expressed on B cells, causing B cell depletion. RTX has shown great efficacy in …

Background: In major depressive disorder (MDD), findings include hyperstable regulation of
brain arousal measured by electroencephalography (EEG) vigilance analysis and …

The pemphigoid group is a category of autoimmune subepidermal blistering diseases in
which autoantibodies deposit linearly at the epidermal basement membrane zone (BMZ) …

Background The use of rituximab for refractory autoimmune blistering diseases is
increasing. Data related to rituximab for the treatment of mucous membrane pemphigoid …

Autoimmune blistering diseases are a heterogeneous group of disorders that mostly affect
the skin and mucous membranes. Occasionally, other organ systems may be involved …

Biologic therapies targeting B-cells are emerging as an effective strategy to treat a variety of
immune-mediated diseases. One of the most studied B-cell-targeted therapies is rituximab …

Purpose The purpose was to evaluate the effectiveness and safety of rituximab (RTX) for the
treatment of patients with aggressive ocular cicatricial pemphigoid (OCP). Methods A review …